Novartis to Present Latest Developments in Blood Disorders, Breast Cancer
Promising data on pediatric relapsed/refractory acute lymphoblastic leukemia to be presented.
Novartis will present the latest data and advancements in the treatment of blood and breast cancers at the upcoming American Society of Hematology (ASH) Annual Meeting and Exposition and the San Antonio Breast Cancer Symposium (SABCS).
The most notable clinical data that Novartis will present is from the ongoing registration trials for CAR T Therapy (CTL019) and LEE011 (ribociclib), according to a press release.
First results from the global registration trial for CTL019 in pediatric relapsed/refractory acute lymphoblastic leukemia will be presented, and data will be included in upcoming regulatory submissions.
Recently, the FDA granted priority review for ribociclib plus letrozole as a first-line treatment for postmenopausal women with HR+/HER2 advanced or metastatic breast cancer. The grant was based on results from the MONALEESA-2 study.
At ASH, Novartis will present safety, efficacy, and quality of life from the company’s hematology portfolio, including the investigational use for nilotinib (Tasigna). Findings will be presented from the post-hoc analysis of Tasigna for treatment-free remission rates in patients who switched from imatinib because of intolerance, resistance, or physical preference.
“Novartis continues to invest in not only creating new medicines for underserved patient communities, but also in redefining cancer treatment goals,” said Novartis CEO Bruno Strigini, in a press release. “Our ASH and SABCS data, including personalized cell and targeted therapies of the future, underscore our core belief in treating each patient as an individual, not just the disease.”